Taysha Gene Therapies, Inc.

TSHA

Explore Our Financial Data > Companies > Taysha Gene Therapies, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TSHA
CIK0001806310
SIC2836
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupBiological Products, Except Diagnostic Substances

Contact

Address3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
Website tayshagtx.com
Phone(214) 612-0000
CEOR. A. Session
Employees180

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$7.22 million
Pre-Tax Income$-86.77 million
Net Income$-86.77 million
Net Income to Common$-86.77 million
EPS$-0.34
View All
Balance Sheet
Cash$116.59 million
Assets$138.36 million
Liabilities$83.30 million
Common Equity$55.06 million
Liabilities & Equity$138.36 million
View All
Cash Flow Statement
Net Income$-86.77 million
Cash From Operating Activities$-83.45 million
Cash From Investing Activities$-594,000.00
Cash From Financing Activities$76.65 million
Change in Cash$-7.39 million
View All
Calculations
NOPAT$-61.98 million
EBITDA$-92.04 million
Price to EarningsN/A
Price to Book$9.55
ROE-159.34%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in conn

Article Link

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Article Link

Cantor Fitzgerald Reiterates “Overweight” Rating on Taysha (TSHA) for Positive TSHA-102 Clinical Data

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 13, Cantor Fitzgerald reiterated its “Overweight” rating and $13.00 price target for Taysha. According to their research note, three key factors played a key role in the analysts’ decision. First, Cantor Fitzgerald’s representatives met […]

Article Link

Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on June 11, Maury Raycroft from Jefferies maintained a Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $8.00. The analyst based the rating on the company’s promising […]

Article Link

Craig-Hallum bullish on Neurogene, initiates with a Buy

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Neurogene (NGNE) with a Buy rating and $50 price target. The firm notes the company is developing NGN-401, an AAV gene therapy for Rett syndrome, a rare and devastating neurodevelopmental disease that impacts girls beginning in infancy and is characterized by developmental regression and symptoms that require lifelong care. Craig-Hallum believes Neurogene is undervalued and that NGN-401 has an elegant design that give

Article Link